for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Westlaw News

Biogen loses bid to block Mylan sales of Tecfidera while patent fight unfolds

An appeals court on Thursday declined to temporarily block Mylan from selling a version of Tecfidera, Biogen’s blockbuster multiple sclerosis drug, while an appeal in patent litigation between the two pharmaceutical companies plays out.

In a brief order, the U.S. Court of Appeals for the Circuit denied a request by Biogen for an injunction that would have halted Mylan’s sales until the court rules on the validity of a key Biogen patent.

To read the full story on Westlaw Today, click here: bit.ly/3ggYjKq

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up